Roivant Sciences Ltd. 8K

Roivant Sciences reported Q1 2026 results, detailed strong liquidity and increased losses, and provided updates on late-stage pipeline programs, a major Moderna patent settlement payment, new Pfizer/BioNTech litigation, and upcoming commercialization and clinical milestones.

On August 6, 2026, Roivant Sciences Ltd. reported financial results for the first quarter ended June 30, 2026 and provided a wide-ranging business update, highlighting ongoing commercial preparations to launch brepocitinib for dermatomyositis by the end of September 2026, progress of multiple late-stage trials for brepocitinib, IMVT-1402 and mosliciguat, as well as significant IP monetization activity through Genevant and Arbutus’ receipt of a $950 million initial payment from Moderna under a $2.25 billion patent settlement and the filing of new international lawsuits against Pfizer and BioNTech. The company disclosed consolidated cash, cash equivalents, restricted cash and marketable securities of $3.9 billion as of June 30, 2026 (excluding the July Moderna payment), a quarterly net loss of $290.6 million (non-GAAP net loss of $243.7 million), increased R&D and G&A expenses largely driven by its anti-FcRn franchise and settlement-related bonuses, and a share repurchase of 7.3 million common shares for approximately $208.7 million, while also outlining key clinical and litigation milestones expected through 2028.

Filing Facts

CIK

1635088

Ticker

ROIV

Form

8K

Source Type

fda

Accession

0001635088-26-000088

Alert Tier

7